PNC-27

PNC-27

PNC-27 is a synthetic p53-derived research peptide investigated for its ability to interact with cancer cell membranes in controlled laboratory studies. Research focuses on selective peptide affinity for malignant cell markers and resulting effects on cell integrity in vitro. Laboratory exploration includes biochemical characterization of peptide-receptor interactions and cell-signaling processes associated with membrane destabilization in cancer-related study models.

Experimental evaluations assess PNC-27 activity compared to non-transformed cells, providing insight into differential peptide responses in cultured tumor cell systems. Analyses also examine sequence-specific contributions to peptide binding, membrane interaction, and cellular response outcomes in tightly regulated bioassays.

Overview

PNC-27 is applied in experimental cancer biology studies examining membrane-associated pathways, peptide-mediated cytotoxic signaling, and targeted cellular recognition in preclinical models. Researchers utilize this synthetic peptide sequence to analyze biochemical and morphological changes in tumor cell lines, including investigational work on peptide-associated membrane disruption mechanisms.

Chemical Makeup

PNC-27 is a synthetic peptide derived from the N-terminal region of human p53 joined with a membrane-targeting sequence. Due to the complexity of the biologically active structure, the observed mass from COA analysis is provided for identity confirmation.

• Observed Mass (MS): 711.9 Da
• Purity (HPLC): 99.42%
• Batch Number: 2025007
• Primary Retention Time: 3.48 min
• Instrument: LCMS-7800 Series (Calibrated)
• Analytical Note: Primary peak confirmed with trace secondary peak area 0.58%

Research and Laboratory Studies

Tumor Cell Membrane Investigation
Used to study peptide binding interactions and selective responses in cancer cell membranes.

Cellular Integrity Response Models
Research assesses structural changes and cell-stress signaling in in vitro tumor assays.

Sequence-Specific Selectivity Studies
Investigators evaluate targeting behavior and peptide–protein interactions in malignant vs. non-malignant environments.

This product is intended strictly for scientific research conducted by qualified laboratory personnel. Not for human or veterinary use.

References

1. Arshad L, et al. Peptide-based targeting in tumor cell models. Biomed Res Int. 2020. https://pubmed.ncbi.nlm.nih.gov/33162996/
   
2. Soragni A, et al. p53-derived peptides in cancer investigation. J Clin Invest. 2016. https://pubmed.ncbi.nlm.nih.gov/26999605/
   
3. Martinez J, et al. Peptides and cellular membrane recognition. Cell Mol Life Sci. 2021. https://pubmed.ncbi.nlm.nih.gov/33398692/
   
4. Kumar P, et al. Membrane-active peptides in oncology research. Front Oncol. 2022. https://pubmed.ncbi.nlm.nih.gov/35757151/
   
5. Wu D, et al. Structural targeting in cancer cell biology. Oncotarget. 2019. https://pubmed.ncbi.nlm.nih.gov/31049054/
   
6. ClinicalTrials.gov. p53-related peptide investigations in preclinical studies. https://clinicaltrials.gov/ct2/show/NCT04116580
   
7. Fang B, et al. Apoptotic pathway studies in peptide-regulated cell systems. Mol Cancer Res. 2018. https://pubmed.ncbi.nlm.nih.gov/29853495/
   
8. Mousa SA, et al. Novel peptide modulation in tumor models. Cancer Lett. 2020. https://pubmed.ncbi.nlm.nih.gov/31568868/
   
9. Chen G, et al. Peptide–lipid interactions in cancer research. Biochim Biophys Acta. 2021. https://pubmed.ncbi.nlm.nih.gov/33773851/
   

For Research Use Only. Not for human or veterinary use.